Spine repair company Benvenue Medical has raised $3.5 million, according to a recent regulatory filing. The filing names individuals from venture capital firms like De Novo Ventures, Domain Associates, Sequent Medical and Technology Partners as investors in the Santa Clara, California firm. It also names Thomas Prescott, CEO of Align Technology that serves the dental market.
Benvenue has developed the Kiva VCF Treatment System and the The Blazer - C Vertebral Augmentation System to treat vertebral compression fractures that result from osteoporosis, benign lesions or malignant lesions. The products are approved in the U.S., Canada and Europe.
Currently, vertebroplasty and kyphoplasty are two minimally invasive procedures used to treat VCFs. In vertebroplasty, thin bone cement is injected into the vertebral body under high pressure. But that created a risk of bone leakage, according to Benvenue Medical. Alternatively, In kyphoplasty a cavity is created with the help of an inflatable balloon and then thicker bone cement is injected under lower pressure to counter the potential for cement leakage.
But the company’s product aims to be an alternative to both these established procedures by using less amount of bone cement.
Aside from treating VCFs, Benvenue Medical intends to use its flexible implant technology as a platform to develop additional spinal therapies such as minimally invasive spinal fusion to treat degenerative disc disease.
The goal is to restore the natural curvature of the spine for patients.